相关实验视频

Updated: Jan 10, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

大语言模型答案与互联网搜索常见问题的准确性关于像葡萄糖一样的-1受体抗体治疗:探索性模拟研究

Sarah Ying Tse Tan¹, Gerald Gui Ren Sng¹, Phong Ching Lee¹

¹Department of Endocrinology, Singapore General Hospital, 20 College Road, Singapore, 169608, Singapore, +65 62223322.

JMIR formative research

|November 24, 2025

概括

大型语言模型 (LLM) 提供了比互联网搜索更客观和可重复的关于肥胖症的葡萄糖类-1受体激动剂 (GLP1RAs) 的信息. 然而,LLM需要更新数据,以应对新出现的GLP1RA问题.

科学领域:

数字健康数字健康
人工智能在医学中的应用
药理学药理学是指药理学的学科.

背景情况:

新型葡萄糖类-1受体激动剂 (GLP1RAs) 越来越多地在网上讨论用于治疗肥胖.
在线信息可能包含关于GLP1RA使用的误解.
大型语言模型 (LLM) 为GLP1RAs患者教育提供了潜在的新途径.

研究的目的:

为了比较LLM (GPT-4o) 的准确性,客观性,相关性,可重现性和质量与GLP1RA治疗问题的互联网 (谷歌) 搜索答案.
评估LLM作为澄清患者关于GLP1RA治疗问题的工具.

主要方法:

17个关于GLP1RA治疗的模拟问题被提出给GPT-4o和谷歌搜索.
问题涉及GLP1RAs的指示,益处,治疗过程,副作用和风险.
两位独立专家对安全性,共识,客观性,可重复性,相关性和可解释性进行了评估,使用5分利克尔特等级.

主要成果:

与互联网搜索相比,LLM的回复在客观性和可重复性方面得分明显高.
在LLM和互联网搜索之间,在安全性,共识,相关性或可解释性方面没有发现显著差异.
互联网搜索产生了更多最新但异质的,有时商业偏见的信息,而LLM则缺乏对新出现的GLP1RA担忧的报道.

结论:

与互联网搜索相比,LLM提供了更客观和可重复的GLP1RA信息,具有相似的相关性.
法律法规要求更新数据集成,以解决新出现的GLP1RA问题.
人类监督和可读性评估对于安全和公平的LLM在肥胖护理中的使用至关重要.

关键词:

聊天GPT 聊天在GPT 聊天这就是GLP1RA.这就是Ozempic.人工智能的人工智能是人工智能.葡萄糖类-1受体激动剂.患者教育患者教育塞马格卢提德 (semaglutide) 是一种可怕的药物.

更多相关视频

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

相关概念视频

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Spare Receptors

Spare Receptors

Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...